JSA Advocates & Solicitors has secured a complete exoneration for GlaxoSmithKline (GSK) before the Competition Commission of India (CCI), bringing one of the longest-running JSA GlaxoSmithKline CCI antitrust matters in the Indian pharmaceutical sector to a close. The CCI closed the proceedings in full, finding no evidence of any anti-competitive conduct by GSK. The order was reported on 30 June 2026.
Introduction
The Competition Commission of India gave a clean chit to pharma companies and industry associations in a 14-year-old case, finding no evidence of anticompetitive agreements or practices in the appointment of stockists and launch of new drugs.
The case, instituted in 2012 on information filed by the All India Chemists and Distributors Federation (AICDF), alleged that the All India Organisation of Chemists and Druggists (AIOCD), its affiliated associations, industry bodies and several pharmaceutical companies were engaged in anti-competitive practices. These related to the appointment of stockists, product launches, trade margins and supply restrictions — with the federation alleging that pharmaceutical companies were required to obtain no-objection certificates before appointing stockists, secure product information service approvals before launching new drugs, and adhere to trade margins fixed under memoranda of understanding with chemist associations.
The case was broader in scope, naming industry associations, state chemist bodies and more than 20 pharmaceutical companies. The CCI ordered a Director General investigation in February 2012 based on prima facie evidence, and the probe was delayed for nearly a decade after proceedings were stayed by the Karnataka High Court in 2012.
JSA successfully represented GSK throughout the proceedings, demonstrating that there was no evidence of any anti-competitive agreement, concerted practice, or participation by GSK in the alleged conduct. The CCI rejected the Director General’s findings and accepted GSK’s submissions entirely.
Legal Teams Involved
Representing GlaxoSmithKline (GSK): JSA Advocates & Solicitors
- Vaibhav Choukse — Lead Partner
- Ela Bali — Partner
- Aditi Khanna — Principal Associate
- Faiz Siddiqui — Senior Associate
- Yaatri Shah — Associate
- Priyanshi Jain — Associate
Significance and Impact
The antitrust watchdog disagreed with the findings of its own investigations arm — the Director General — which had found the parties to be in contravention of the Competition Act. The CCI’s order stated: “The commission is of the considered opinion that no case of contravention of the provisions of Section 3 of the Act is made out against any of the opposing parties.”
The regulator further stressed that the material on record indicated that several pharmaceutical companies themselves had complained of boycott threats, supply disruptions and pressure exerted by associations affiliated with AIOCD — suggesting that “such companies were, at best, passive recipients or victims of prevailing trade practices rather than willing participants in any anti-competitive arrangement.”
Pharmaceutical companies including Dr. Reddy’s Laboratories, Pfizer, GlaxoSmithKline Pharmaceuticals and Torrent Pharmaceuticals were among those cleared of long-running antitrust allegations after the CCI closed the 14-year-old case having found insufficient evidence.
The ruling carries significant weight for the Indian pharmaceutical industry. It establishes that mere compliance with — or passive acceptance of — prevailing trade association practices does not constitute willing participation in an anti-competitive arrangement under Section 3 of the Competition Act, 2002. For multinational pharmaceutical companies operating in India’s complex distribution ecosystem, the order reinforces that regulatory compulsion and commercial vulnerability are substantively distinct from cartel conduct.
The outcome also underscores the value of sustained, evidence-driven competition defence in matters involving prolonged regulatory scrutiny. The CCI’s willingness to depart from its Director General’s own findings — after over 14 years of proceedings — reflects the rigour with which the Commission examined the record in this case.
For a broader view of how Indian law firms are performing in high-stakes regulatory mandates, visit the Deal Meter.
JSA Advocates & Solicitors‘ successful defence of GlaxoSmithKline before the CCI marks the conclusion of one of the most prolonged antitrust investigations in India’s pharmaceutical sector. The Commission’s order, which rejected the Director General’s findings and completely exonerated GSK, affirms that passive recipients of trade practices cannot be treated as willing participants in anti-competitive arrangements. Further details on the broader proceedings were not disclosed.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. It is based on the details provided and publicly available sources.
